source
- CSL strikes up to $1.6B deal with Alentis for autoimmune drug with broad potentialCSL will co-develop and co-promote Alentis Therapeutics' anti-claudin-1 therapy lixudebart for kidney and liver conditions, including primary sclerosing cholangitis and a systemic autoimmune diseas…
- Diagnostic-driven therapies face patient loss due to workflow gaps, new commercialization model proposedThe sponsored article from Diaceutics highlights that while diagnostic-driven therapies are being developed faster than ever, many patients who could benefit never receive them. The authors attribu…